Shares of Biogen jumped more than 11 percent after the company announced the U.S. Food and Drug Administration accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.
The U.S. Food and Drug Administration accepted for review Orion and Bayer’s New Drug Application for darolutamide for the treatment of non-metastatic castration-resistant prostate cancer.
The U.S. FDA accepted Novartis’ New Drug Application for the investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
